Kyle Munz

6 days ago | ajmc.com | Kyle Munz |Pierluigi Porcu

As treatment advances continue to reshape chronic lymphocytic leukemia (CLL) care, clinicians face the growing challenge of aligning clinical efficacy with long-term cost sustainability, explained Pierluigi Porcu, MD, director, Division of Hematologic Malignancies, Jefferson Health. To strike this balance, he argued, will take a more holistic understanding of the patient factors and available resources that could impact their treatment.

1 week ago | ajmc.com | Kyle Munz |Naim Alkhouri

Over the past decade, the treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) has undergone significant transformation, explained Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver Program at Arizona Liver Health.

1 week ago | ajmc.com | Kyle Munz

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) carry an increased risk for cardiovascular complications.

1 week ago | ajmc.com | Kyle Munz

Moving forward in clinical research involves answering simple questions: Can you explain why it matters? Can you get someone to pay for it? These are questions of health policy, said Theresa W. Gillespie, PhD, MA, FAAN, associate director for cancer health equity and community engagement at Winship Cancer Institute of Emory University.

2 weeks ago | ajmc.com | Kyle Munz |Joseph J. Saseen

The negative impact of lipoprotein a (Lp[a]) and its association with cardiovascular disease and complications is well known, explained Joseph Saseen, PharmD, University of Colorado. Not only should clinicians be aware of their patient’s status, but the patients and their loved ones as well, he added. Because genetics can influence Lp(a), enhancing patient education and awareness are of utmost importance.